We evaluated a monoclonal fluorescent-antibody (FA) reagent (Neisseria gonorrhoeae Culture Confirmation Test; Syva Co., Palo Alto, Calif.) for confirmation of N. gonorrhoeae isolates obtained from clinics for sexually transmitted diseases in four cities. The FA test was performed in parallel with established confirmation procedures on all organisms growing on 773 primary culture plates of modified Thayer-Martin agar. All N. gonorrhoeae isolates reacted with the FA reagent and produced a bright, easily interpretable fluorescence. The FA test correctly identified 533 N. gonorrhoeae isolates from 474 patients and did not react with 90 N. meningitidis or with 213 non-Neisseria isolates. In one city (Baltimore), Gonochek II (Du Pont Co., Wilmington, Del.) failed to identify four N. gonorrhoeae isolates reactive with the FA reagent and confirmed as N. gonorrhoeae by Phadebact (Pharmacia Inc., Piscataway, N.J.) and acid production from sugars. The FA test was rapid and specific and could be performed directly from primary isolation plates. The test requires 1 h to perform and is applicable to mixed-flora cultures.
Differentiation of Neisseria gonorrhoeae from other gramnegative diplococci isolated from mucosal surfaces is important for guiding therapy. Laboratory misidentification of organisms as N. gonorrhoeae has potentially serious medical, legal, and social consequences for patients, their partners, and care providers (2) . Acid reactions from sugars and nitrate reduction are the standards to which other methods of culture confirmation are compared (7) . However, these methods are occasionally compromised by limited or unpredictable growth of N. gonorrhoeae in broth or semisolid media (1, 3, 10) . More rapid methods for identification based on serological reactions and detection of preformed enzymes have been developed but often require subculture of isolates to provide adequate cellular mass for testing (4, 9) . Fluorescent antibodies (FA) for culture confirmation have the advantage of requiring only growth from a primary isolation plate. The high specificity of monoclonal antibodies offers the potential for improvement over available polyclonal fluorescein-conjugated reagents which have been reported to cross-react with Branhamella catarrhalis (7) .
In this study, we evaluated a new monoclonal FA reagent (Neisseria gonorrhoeae Culture Confirmation Test; Syva Co., Palo Alto, Calif.) for confirmation of N. gonorrhoeae in cultures of clinical specimens from a variety of mucosal sites. The FA reagent contains monoclonal antibodies prepared against purified outer membrane protein I of N. gonorrhoeae and is formulated to react with serovars containing outer membrane proteins IA and IB (Syva Co., personal communication). The description of the development of these antibodies has been published by Tam et Denver, Indianapolis, and Seattle) were studied to control for variation in the geographical distribution of gonococcal serovars (6) . In each laboratory, the FA reagent was compared with the test(s) routinely used in that laboratory for the identification of N. gonorrhoeae. In addition, reagent specificity was examined by assessing cross-reactivity with all nongonococcal colonial morphotypes growing on primary culture plates. 90, 1987) .
MATERIALS
The FA format for a confirmatory test permitted expeditious evaluation of colonies from crowded primary plates without requiring subculture. The FA test could be an advantageous alternative for laboratories using acid production tests, since contamination is the most common problem in the traditional confirmation of N. gonorrhoeae. Similarly, laboratories have encountered difficulties with atypical strains of N. gonorrhoeae which utilize glucose poorly or with strains of N. meningitidis which fail to produce acid from maltose (1, 8) . Culture-related problems such as these would be obviated by a reliable, specific FA procedure.
An important additional benefit of the FA test is that it demonstrates the microscopic appearance of isolates, as well as the antibody reactivity. By using oil-immersion microscopy, organisms could be readily visualized as typical kidney bean-shaped diplococci. Thus, microscopic examination adds a level of confidence above that of chromogenic sub- This monoclonal FA reagent may also prove useful for clinical settings for which primary culture is performed at one site, such as a physician's office, and confirmatory testing is performed elsewhere, such as a distant laboratory. Viable N. gonorrhoeae are not required for FA reactivity and flooding plates with the oxidase reagent before testing does not affect test interpretation (unpublished data).
Although this study evaluated the use of FA for culture confirmation of isolates from a clinic for sexually transmitted diseases, the specificity of this reagent for strains from nonmucosal sites (blood, joint fluid, spinal fluid) or from children needs to be evaluated. In these situations other species of gram-negative diplococci may be pathogenic; thus, laboratories should confirm the identification of N. gonorrhoeae with other methods of speciation.
The cost of the FA reagent may limit its application in some laboratories. Currently, the list price of one 3-ml vial is $275, or approximately $3.25 per test. The manufacturer is offering high-volume pricing which may lower the cost substantially. Decisions on the cost effectiveness of the FA procedure must be weighed against the costs involved in subculture and repetitious testing of strains with variable biochemical reactions.
Nonetheless, we found the N. gonorrhoeae fluorescent monoclonal antibody test to be useful in high-volume clinics for sexually transmitted diseases where multiple specimens can be batched for culture confirmation. The test is rapid and 100% specific for N. gonorrhoeae isolates recovered from representative urban populations in the United States.
